Relationship of Serum Dehydroepiandrosterone (DHEA), DHEA Sulfate, and 5-Androstene-3β,17β-diol to Risk of Breast Cancer in Postmenopausal Women

Joanne F. Dorgan,1 Frank Z. Stanczyk, Christopher Longcope, Hugh E. Stephenson, Jr., Lilly Chang, Rosetta Miller, Charlene Franz, Roni T. Falk, and Lisa Kahle

Division of Cancer Prevention and Control, National Cancer Institute, NIH, Bethesda, Maryland 20892-7326 [J. F. D.]; Department of Obstetrics and Gynecology, Women’s Hospital, University of Southern California School of Medicine, Los Angeles, California 90033 [F. Z. S., L. C.]; Departments of Obstetrics and Gynecology and Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 01655 [C. L. C. F.]; Department of Surgery, University of Missouri Health Sciences Center, Columbia, Missouri 65212 [H. E. S.]; Cancer Screening Services, Ellis Fischel Cancer Center, Columbia, Missouri 65203 [R. M.]; Division of Cancer Etiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland 20892 [R. T. F.]; and Information Management Services, Inc., Silver Spring, Maryland 20904 [L. K.]

Abstract
Laboratory evidence suggests a role for dehydroepiandrosterone (DHEA) and its metabolite 5-androstene-3β,17β-diol (ADIOL) in mammary tumor growth. Serum DHEA also has been related to breast cancer in postmenopausal women, but the relationship of ADIOL to risk has not been evaluated previously. To assess the relationship of serum DHEA, its sulfate (DHEAS), and ADIOL with breast cancer risk in postmenopausal women, we conducted a prospective nested case-control study using serum from the Columbia, MO Breast Cancer Serum Bank. Cases included 71 healthy postmenopausal volunteers not taking replacement estrogens when they donated blood and who were diagnosed with breast cancer up to 10 years later (median, 2.9 years). Two randomly selected controls, who also were postmenopausal and not taking estrogens, were matched to each case on exact age, date (±1 year), and time (±2 h) of blood collection. Significant (trend \( P = 0.02 \)) gradients of increasing risk of breast cancer were observed for increasing concentrations of DHEA and ADIOL, and women whose serum levels of these hormones were in the highest quartiles were at a significantly elevated risk compared to those in the lowest; their risk ratios were 4.0 (95% confidence interval [CI], 1.3–11.8) and 3.0 (95% CI, 1.0–8.6), respectively. The relationship of DHEAS to breast cancer was less consistent, but women whose serum DHEAS concentration was in the highest quartile also exhibited a significantly elevated risk ratio of 2.8 (95% CI, 1.1–7.4).

Results of this prospective study support a role for the adrenal androgens, DHEA, DHEAS, and ADIOL, in the etiology of breast cancer.

Introduction
In the Washington County, MD, cohort, serum levels of DHEA were elevated in postmenopausal women who subsequently were diagnosed with breast cancer (1), but they were depressed in premenopausal women who developed breast cancer (2). Furthermore, in postmenopausal breast cancer patients, 24-h mean plasma levels of DHEA and DHEAS were raised, but in premenopausal patients they were lowered (3). Similarly, DHEA has been reported to stimulate 7,12-dimethylbenz(a)anthracene-induced mammary tumor growth in oophorectomized rats but to decrease tumor progression in intact animals with higher circulating estradiol levels (4). The apparent dual character of the action of DHEA may be due to its metabolite ADIOL, which in vitro can act as an estrogen or androgen depending on the estradiol concentration of the medium. ADIOL binds to the estrogen receptor and at physiological concentrations has been shown to stimulate proliferation of estrogen-sensitive MCF-7 breast cancer cells grown in estradiol-deficient medium (5–7). However, when MCF-7 cells were grown in estradiol-rich medium, estrogen receptors were occupied and ADIOL acted as an androgen, inhibiting cell proliferation (8).

Because serum estradiol concentrations of post-menopausal women are low relative to premenopausal women, the opposite associations of DHEA with breast cancer reported previously for pre- and postmenopausal women could be explained by its metabolite ADIOL. We, therefore, used the Columbia, MO, Breast Cancer Serum Bank established as part of the National Cancer Institute’s Biological Markers Program to evaluate the relationship of DHEA, its sulfate (DHEAS), and ADIOL with the subsequent development of breast cancer in postmenopausal women.

Materials and Methods
The study, which utilized a prospective nested case-control design, has been described in detail previously (9). Participants were volunteers identified through three sources: the Breast Cancer Detection Demonstration Project; Women’s Cancer Control Program at the Cancer Research Center, the University of Missouri Health Sciences Center; and the Ellis Fischel Cancer Center (Columbia, MO). A total of 7224 women who initially were free of breast cancer donated blood to the bank on

Received 7/12/96; revised 11/21/96; accepted 11/22/96.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 To whom requests for reprints should be addressed, at Division of Cancer Prevention and Control, National Cancer Institute, Executive Plaza North, Room 211, 6130 Executive Boulevard, Bethesda, MD 20892-7326.

2 The abbreviations used are: DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulfate; ADIOL, 5-androstene-3β,17β-diol; FSH, follicle-stimulating hormone; RR, risk ratio; CI, confidence interval; ACTH, adrenocorticotropic hormone.
one or more occasions. Recruitment into the cohort was ongo-
ing between 1977 and 1987, although over 90% of the women
first gave blood in 1980 or earlier. Active follow-up by mail
continued until 1989, but 70% of the cohort were last contacted
in 1982–1983, at least partly because of funding changes. At the
time of last contact, 91% of the total cohort were alive and free
of breast cancer, 2% had been diagnosed with breast cancer,
and 5% were dead from a cause other than breast cancer.
Pathology reports were obtained for all women who reported a
positive breast biopsy or mastectomy on follow-up.

Women included in the current study were restricted to
those who had at least 4 ml of blood remaining in the bank and
who, at the time of blood collection, had no history of cancer
other than nonmelanoma skin cancer, were not diagnosed with
benign breast disease within the past 2 years, were postmeno-
pausal, and did not report taking replacement estrogens.
Women were classified initially as postmenopausal if they
reported natural menopause, bilateral oophorectomy, or radia-
tion to the ovaries prior to blood collection or were at least 51
years of age at blood collection with a history of hysterec-
omy without oophorectomy. Final determination of menopausal
status was based on serum FSH levels. Any woman with a FSH
less than 35 mIU/ml was considered potentially premenopausal,
and her reported date of last menses, age, and hormonal profile
were reviewed to determine eligibility.

Of the 3375 women who met these criteria, 72 subsequently
were diagnosed with histologically confirmed breast cancer. For
each of these cases, two controls were selected from among the
eligible women using incidence-density sampling. Controls were
alive and free of cancer (except nonmelanoma skin cancer) at the age of
the case’s diagnosis and were matched to the case on exact age at
blood collection and on the date (±1 year) and time (±2 h) of the
blood draw. Two controls who met the matching criteria could not
be identified for 12 cases. For these cases, matching criteria were
relaxed as follows: (a) age, ±1 year (n = 8); (b) blood draw, ±2
years (n = 3); and (c) age, ±4 years and blood draw date ±2 years
and time ±4 h (n = 1). Following review of FSH results, one case
and four controls were dropped because they were premenopausal,
and one control was dropped because her hormone profile was
consistent with exogenous estrogen use. This left 66 case-control
sets with two controls and 5 case-control sets with one control for
analysis.

Serum specimens were collected, and clinical data, including
age, height, weight, menstrual and reproductive histories, smok-
ing, medication (including hormone) use, and family history of
breast cancer, were obtained by self-report or medical record
review after obtaining informed consent. Approximately 10 ml of
serum was collected from each woman using standard procedures.
Blood was chilled immediately and serum was separated and
 aliquoted into glass vials within 2 h of collection. Serum was
 shipped on dry ice to the Mayo Foundation repository, where it
was maintained at -70°C until analysis. Blood was stored for a
median of 16 years prior to analysis for both cases and controls.

Serum from each case and her matched control(s) were
grouped and analyzed together in the same batch. DHEA,
DHEAS, and ADIOL were measured by specific RIAs. A direct
RIA kit (ICN Biomedicals, Inc., Costa Mesa, CA) was used to
quantify DHEAS, after dilution of the serum samples. DHEA and
ADIOL were extracted with hexane:ethyl acetate (3:2) and then
chromatographed on cellulose impregnated with ethylene glycol prior
to RIA. Elution of DHEA was carried out with 25% toluene in
isoctane, and elution of ADIOL was carried out with 100%
toluene. Separation of antibody-bound and -unbound steroids in
the RIA was achieved by use of dextran-coated charcoal. Internal
standards ([^3]HDHEA and [^3]HADIOL, 1000 dpm (<3 pg of
each)) were added to follow procedural losses that averaged 25%.
Intra- and interassay coefficients of variation of logr-transformed
hormone levels in blind replicate quality-control samples included
in each batch ranged between 1.0–4.1% and 2.5–6.1%, respec-
tively, for all three hormones.

Geometric mean hormone levels for cases and controls
were compared using Student’s t tests (10). The relationship of
serum hormones to breast cancer risk for the matched sets were
evaluated using conditional logistic regression (11). Women
were stratified into quartiles based on their hormone levels
relative to the distribution of hormone values in controls and a
set of categorical (dummy) variables was included in models.
RRs were estimated as the antilogs of the regression coeffi-
cients. Models also were fit using quartile medians to test for
trends. To adjust for known breast cancer risk factors, time
since menopause, height, weight, parity, and family history of
breast cancer were included in models. Time since menopause
was modeled as a set of categorical variables using the distri-
bution in controls to define cut points, parity was modeled as
parous versus nulliparous, and height and weight were modeled
as continuous variables. To evaluate the joint effects of two
hormones simultaneously, women were categorized into three
groups as follows: (a) those in the lowest quartile for both
hormones, (b) those in the highest quartile for both hormones,
and (c) all other women. Models were then fit using categorical
(dummy) variables. Interactions of hormone levels with age (a
matching criterion) and breast cancer risk factors included in
adjusted models were tested by including cross products terms
in models. Because of small numbers, analyses stratified by
time from blood collection to cases’ diagnoses were unadjusted
and participants were categorized into tertiles rather than
quartiles. All analyses were performed using SAS Statistical
Software (12).
Table 1  Characteristics of cases and controls at blood collection

<table>
<thead>
<tr>
<th></th>
<th>Cases (n = 71)</th>
<th>Controls (n = 133)</th>
<th>P value&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at blood collection (yr)</td>
<td>61</td>
<td>62</td>
<td>0.53</td>
</tr>
<tr>
<td>Age at menopause (yr)</td>
<td>50</td>
<td>50</td>
<td>0.66</td>
</tr>
<tr>
<td>Time since menopause at blood collection (yr)</td>
<td>11.1</td>
<td>12.4</td>
<td>0.49</td>
</tr>
<tr>
<td>Age at menarche (yr)</td>
<td>13</td>
<td>13</td>
<td>0.38</td>
</tr>
<tr>
<td>Parity</td>
<td>2</td>
<td>3</td>
<td>0.06</td>
</tr>
<tr>
<td>Age at first pregnancy (yr)</td>
<td>24</td>
<td>23</td>
<td>0.83</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>165</td>
<td>160</td>
<td>0.02</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>68</td>
<td>65</td>
<td>0.24</td>
</tr>
<tr>
<td>Body mass index (kg/m&lt;sup&gt;2&lt;/sup&gt;)</td>
<td>26.0</td>
<td>25.2</td>
<td>0.44</td>
</tr>
</tbody>
</table>

<sup>a</sup> P values from Wilcoxon rank-sum test.

Table 2  Dates of blood collection and diagnosis for cases (years)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood collection</td>
<td>2</td>
<td>41</td>
<td>19</td>
<td>5</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>3</td>
<td>6</td>
<td>15</td>
<td>6</td>
<td>19</td>
<td>4</td>
<td>8</td>
<td>2</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>2</td>
</tr>
</tbody>
</table>

Table 3  Geometric mean serum hormone levels for cases and controls

<table>
<thead>
<tr>
<th></th>
<th>Cases (n = 71)</th>
<th>Controls (n = 133)</th>
<th>P value&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean 95% CI</td>
<td>Mean 95% CI</td>
<td></td>
</tr>
<tr>
<td>DHEA (nm)</td>
<td>6.57 5.61-7.70</td>
<td>5.34 4.74-6.01</td>
<td>0.04</td>
</tr>
<tr>
<td>DHEAS (μM)</td>
<td>2.41 2.03-2.87</td>
<td>2.01 1.80-2.25</td>
<td>0.08</td>
</tr>
<tr>
<td>Androstenediol (nm)</td>
<td>1.14 0.98-1.33</td>
<td>0.97 0.88-1.07</td>
<td>0.07</td>
</tr>
</tbody>
</table>

<sup>a</sup> P value (two-sided) from t test.

Table 4  Relationship of serum hormones to breast cancer risk

<table>
<thead>
<tr>
<th></th>
<th>Number of participants</th>
<th>Unadjusted&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Adjusted&lt;sup&gt;c&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cases  Controls</td>
<td>RR 95% CI</td>
<td>RR 95% CI</td>
</tr>
<tr>
<td>DHEA (nm)</td>
<td>&lt;3.18</td>
<td>10 32</td>
<td>1.0 1.0</td>
</tr>
<tr>
<td></td>
<td>3.18-5.58</td>
<td>17 33</td>
<td>1.7 0.7-4.5</td>
</tr>
<tr>
<td></td>
<td>5.59-8.94</td>
<td>18 33</td>
<td>1.8 0.7-4.3</td>
</tr>
<tr>
<td></td>
<td>&gt;8.95</td>
<td>25 33</td>
<td>2.5 1.0-6.2</td>
</tr>
<tr>
<td>DHEAS (μM)</td>
<td>&lt;1.32</td>
<td>13 33</td>
<td>1.0 1.0</td>
</tr>
<tr>
<td></td>
<td>1.32-2.19</td>
<td>19 31</td>
<td>1.4 0.6-3.4</td>
</tr>
<tr>
<td></td>
<td>2.20-3.17</td>
<td>8 34</td>
<td>0.6 0.2-1.8</td>
</tr>
<tr>
<td></td>
<td>&gt;3.18</td>
<td>31 35</td>
<td>2.2 1.0-5.2</td>
</tr>
<tr>
<td>Androstenediol (nm)</td>
<td>&lt;0.62</td>
<td>10 32</td>
<td>1.0 1.0</td>
</tr>
<tr>
<td></td>
<td>0.62-1.00</td>
<td>16 32</td>
<td>1.6 0.6-4.1</td>
</tr>
<tr>
<td></td>
<td>1.01-1.49</td>
<td>19 32</td>
<td>1.8 0.7-4.4</td>
</tr>
<tr>
<td></td>
<td>&gt;1.50</td>
<td>25 33</td>
<td>2.4 1.0-6.0</td>
</tr>
</tbody>
</table>

<sup>b</sup> Matched on age, year, and time of day of blood collection.
<sup>c</sup> Adjusted for years since menopause, height, weight, family history of breast cancer, and parity.

was significant, and women in the highest quartile of DHEAS were at a significant increased risk of developing breast cancer, women in the third quartile had the lowest risk. These inconsistencies were not an artifact of quartile cut points, because a similar pattern of risks was observed when women were categorized into quintiles. They may, however, have been related to our fairly small sample size, because a trend became apparent when women were categorized into tertiles; compared to women in the lowest tertile, RRs for women in the upper two tertiles for DHEAS were 1.3 (95% CI, 0.6-2.8) and 2.0 (95% CI, 0.9-4.2), respectively.

Analysis of the joint effects of DHEA and ADIOL on breast cancer risk suggest additivity. Compared to women in the lowest quartile for both hormones, the RR for women in the highest quartile for both was 6.2 (95% CI, 1.7-23.7). Women with all other combinations of levels of these hormones, con-
Serum Hormones and Breast Cancer Risk

Considered as a single group, had an intermediate RR of 3.4 (95% CI, 1.1–10.6). When similar analyses were performed for DHEAS with each of the other two hormones, RRs for women in the highest quartiles for both hormones did not differ materially from those for the individual hormones shown in Table 4. Compared to women in the lowest quartile for DHEAS and ADIOL, women in the highest quartile for both of these hormones had a RR of 3.5 (95% CI, 1.1–12.0). The RR from a similar analysis for DHEA and DHEAS combined was 3.4 (95% CI, 1.0–11.0).

No significant (P = 0.05) interactions between hormones and breast cancer risk factors were detected. Furthermore, as shown in Table 5, when we limited analysis to the 46 cases whose blood was collected more than 2 years prior to diagnosis, women in the upper tertile for DHEA, ADIOL, and DHEAS were at the highest risk of developing breast cancer.

Because of concerns about potential bias stemming from incomplete follow-up, we also re-evaluated associations of hormones with breast cancer after truncating the study period at 1982–1983, when follow-up was greater than 90% complete. During this early phase of the study, 53 breast cancers were diagnosed. Risk of breast cancer in this subgroup in relation to serum levels of hormones did not differ materially from those reported for the entire cohort. Increasing gradients of risk with increasing serum levels were apparent for DHEA and ADIOL. Adjusted for years since menopause, height, weight, family history of breast cancer, and parity, RRs by increasing quartile of DHEA were 1.0, 2.3 (95% CI, 0.7–7.3), 4.2 (95% CI, 1.2–14.7), and 4.9 (95% CI, 1.2–20.2). For ADIOL, the analogous RRs were 1.0, 1.1 (95% CI, 0.3–3.6), 2.0 (95% CI, 0.6–6.4), and 2.7 (95% CI, 0.8–8.9). As with the entire cohort, the risk of breast cancer in relation to serum DHEAS was inconsistent, but women in the highest quartile were at greatest risk.

Of the 53 cases diagnosed in 1983 or earlier, 29 (55%) were diagnosed more than 2 years after blood collection. When we restricted analysis to this subset of women, trends in risk across tertiles were not apparent for any of the hormones, but women in the highest tertile for each hormone were at an increased risk of breast cancer. Compared to women in the lowest tertile, RRs for those in the highest were 2.4 (95% CI, 0.7–8.4) for DHEA, 2.3 (95% CI, 0.7–7.5) for ADIOL, and 2.6 (95% CI, 0.9–3.0) for DHEAS.

### Table 5  Unadjusted RRs of breast cancer for tertiles of serum hormone levels by time from blood collection to diagnosis in cases

<table>
<thead>
<tr>
<th>Hormone</th>
<th>≤2 years (n = 25 cases)</th>
<th>&gt;2 years (n = 46 cases)</th>
</tr>
</thead>
<tbody>
<tr>
<td>RR</td>
<td>95% CI</td>
<td>RR</td>
</tr>
<tr>
<td>DHEA (&lt;nm)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;4.36</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>4.36–7.52</td>
<td>2.2</td>
<td>0.5–9.8</td>
</tr>
<tr>
<td>7.53–10.69</td>
<td>1.3</td>
<td>0.3–5.3</td>
</tr>
<tr>
<td>DHEAS (&lt;µg)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;1.55</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>1.55–2.87</td>
<td>1.4</td>
<td>0.4–4.9</td>
</tr>
<tr>
<td>2.88–+</td>
<td>1.3</td>
<td>0.4–4.9</td>
</tr>
<tr>
<td>Androstenediol (&lt;nm)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;0.80</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>0.80–1.28</td>
<td>1.3</td>
<td>0.4–4.8</td>
</tr>
<tr>
<td>1.28–+</td>
<td>0.8</td>
<td>0.3–2.4</td>
</tr>
</tbody>
</table>

Discussion

This is the first epidemiological study to evaluate the relationship between serum ADIOL and breast cancer risk in postmenopausal women. Our finding of a significant positive association is consistent with results of in vitro laboratory studies that have shown ADIOL to cause proliferation of breast cancer cells grown in estradiol-deficient medium (5–7, 13). The positive association that we observed between DHEA and breast cancer in postmenopausal women is in agreement with results of Gordon et al. (1) and is consistent with enhancement by DHEA of 7,12-dimethylbenz(a)anthracene-induced mammary tumorigenesis in oophorectomized rats (4). Because of the small numbers, we were unable to investigate associations of hormones with premenopausal breast cancer.

The age-adjusted incidence of breast cancer among women 50 years of age and older in the cohort was 128 per 100,000 person-years followed, which is less than the average incidence of 289 per 100,000 per year reported for white women of the same age by the Surveillance, Epidemiology, and End Results Program during the period of case ascertainment for the study (14). The lower rate in our cohort may have been due to a lower incidence of breast cancer in the community, a lower incidence among women who volunteered to participate in the study, or incomplete follow-up. If the latter is correct, bias could have been introduced if serum hormones were related to follow-up, and this association differed for women who did and did not develop breast cancer.

Because data on response rates were not tabulated during the conduct of the study and these records were destroyed at completion of the contract, statistics on response rates cannot be reported. However, our findings of similar associations between serum hormones and breast cancer over the entire study period and during the early phase, when follow-up was more than 90% complete, suggest that the associations we observed were not biased by incomplete follow-up.

DHEAS is the most abundant steroid in human serum and is secreted solely by the adrenal cortex. The adrenal cortex also is the primary source of serum DHEA and ADIOL as a result of direct secretion and peripheral conversion of adrenal hormones (15–17). Control of secretion of adrenal androgens is not understood completely, but, at least in part, it is regulated by ACTH (16, 17). ACTH is elevated in response to stress (18), which to our knowledge has not been investigated prospectively in relation to breast cancer. ACTH levels also increase in response to alcohol ingestion (19), which has been positively associated with postmenopausal breast cancer risk in numerous epidemiological studies (20–25).

Estradiol has the strongest binding affinity for the estrogen receptor, and as we reported previously (9), serum levels may be important in determining breast cancer risk. ADIOL also binds the estrogen receptor but with 1:25 the affinity of estradiol (5). However, given that the serum concentration of ADIOL is much higher than estradiol in postmenopausal women (20:1 in our controls), circulating ADIOL could be an important source of estrogenic stimulation of breast tumor growth.

Whereas ADIOL, because of its high affinity for the estrogen receptor, could act directly as a breast cancer promoter, DHEA has only poor affinity for the estrogen receptor and is more likely to increase breast cancer risk by conversion to ADIOL or other metabolites (5, 26). DHEA levels have been reported to be higher in blood supplying than in blood draining tumor-bearing breasts (27, 28), and in one study, the arteriovenous gradient in DHEA plasma concentration was positively correlated with tumor DHEA content, suggesting uptake of
DHEA by tumors (28). Some breast tumors have been shown to possess the enzymes required to metabolize DHEA to ADIOL (5–7, 29–31) and estradiol (32, 33). Normal breast tissue also could potentially metabolize DHEA to other androgens or estrogens and stimulate tumor growth in a paracrine fashion.

The relationship of DHEAS with breast cancer risk in our data was less clear than that of DHEA or ADIOL. Although the test for trend was significant and women in the fourth (highest) quartile for DHEAS were at elevated risk for breast cancer, women in the third quartile were at the lowest risk. Furthermore, women with elevated DHEAs in addition to DHEA or ADIOL were not at a greater risk of breast cancer than women with elevated levels of each of these hormones alone, indicating that the suggested association of DHEAS with breast cancer in our data may have been due to its correlation with other hormones. In the study by Gordon et al. (1, DHEA, but not DHEAS, was related to breast cancer risk. However, Japanese women, who have a lower breast cancer risk compared to Western women, particularly after menopause, also have lower DHEAS levels (34).

We previously reported positive associations of testosterone and non-sex hormone-binding globulin-bound estradiol with breast cancer in these same women (9). The addition of DHEA, ADIOL, and possibly DHEAS strongly suggests a role for adrenal androgens in the etiology of breast cancer, at least in postmenopausal women.

Acknowledgments
We acknowledge Dr. Alain Belanger (Laval University Hospital Center, St. Foy, Quebec, Canada), for generously providing the ADIOL antiserum.

References
Relationship of serum dehydroepiandrosterone (DHEA), DHEA sulfate, and 5-androstene-3 beta, 17 beta-diol to risk of breast cancer in postmenopausal women.

J F Dorgan, F Z Stanczyk, C Longcope, et al.


Updated version
Access the most recent version of this article at:
http://cebp.aacrjournals.org/content/6/3/177

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.